The Cancer Center Administration team provides centralized infrastructure and support that enables the City of Hope Comprehensive Cancer Center to function effectively, efficiently, and cohesively. Administration works with other Center leadership to foster collaborations, and support cancer focused research through infrastructure, pilot projects, and faculty recruitment. Administration's specific duties include: * Administrative planning to promote and facilitate scientific collaborations and interactions * Strategic planning leadership and implementation of initiatives * Management and evaluation of Cancer Center Membership * Fiscal control and management of Cancer Center accounts ensuring compliance with all COH institutional policies and federal requirements * Management, logistics support and documentation of senior leadership committees, retreats and programmatic meetings * Coordination of information technology required for internal and external data reporting *Coordination of planning and evaluation of Shared Resources * Management, processing and monitoring of CC pilot project competitions *Cataloguing of all CC programmatic meetings and retreats Recent accomplishments of the Administration Team include successful development of new Shared Resources and establishment of a new Shared Resources reporting system, review/restructure of membership, and completion of a new strategic plan. Funding is requested to cover a portion of the salary for these efforts and to cover a portion of the costs for the Cancer Center seminar series. The majority of the costs for Administration are covered by institutional funds. The Administration budget request represents 4.1% of the overall CCSG budget requested in this application.
Cancer Center Administration provides centralized leadership and support for multiple functions including strategic planning, membership, pilot project competitions, educational seminars, senior leadership meetings and Shared Resources. This responsibility enhances the Cancer Center's dedication to providing a leadership structure which contributes to the coordination and collaboration of research efforts.
|Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828|
|Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118|
|Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141|
|Yim, John H; Choi, Audrey H; Li, Arthur X et al. (2018) Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics. Clin Cancer Res :|
|Wang, Tianyi; Fahrmann, Johannes Francois; Lee, Heehyoung et al. (2018) JAK/STAT3-Regulated Fatty Acid ?-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab 27:136-150.e5|
|Magilnick, Nathaniel; Boldin, Mark P (2018) Molecular Moirai: Long Noncoding RNA Mediators of HSC Fate. Curr Stem Cell Rep 4:158-165|
|Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171|
|Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520|
|Slavin, Thomas P; Banks, Kimberly C; Chudova, Darya et al. (2018) Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol :JCO1800328|
|Shahin, Sophia A; Wang, Ruining; Simargi, Shirleen I et al. (2018) Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine 14:1381-1394|
Showing the most recent 10 out of 1396 publications